Peculiar Pattern of Response Following [²²⁵Ac]Ac-PSMA Therapy: A Case Report with ‘PSA Pseudoregression’ Response Pattern

Keywords

Prostate cancer - mCRPC - PSMA - Actinium-225 - Pseudoregression - Unusual Pattern

Publication History

Received: 24 January 2024

Accepted after revision: 22 April 2024

Article published online:
17 May 2024

• References

• 1 Al-Ibraheem A. Theranostics in Developing Countries: Addressing Challenges and Potentials from Training to Practice. World J Nucl Med 2023; 22 (03) 171-173
• 2 Cerci JJ, Fanti S, Lobato EE. et al. Diagnostic performance and clinical impact of 68Ga-PSMA-11 PET/CT imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA Study). J Nucl Med 2022; 63 (02) 240-247
• 3 Hennrich U, Eder M. 177Lu] Lu-PSMA-617 (PluvictoTM. Pharmaceuticals 2022; 15 (10) 1292
• 4 Delker A, Fendler WP, Kratochwil C. et al. Dosimetry for 177 Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 42-51
• 5 Al-Ibraheem A, Scott AM. 161Tb-PSMA Unleashed: a Promising New Player in the Theranostics of Prostate Cancer. Nucl Med Mol Imaging 2023; 1-4
• 6 Satapathy S, Sood A, Das CK. et al. Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer—A systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2021; 24 (03) 880-890
• 7 Manafi-Farid R, Harsini S, Saidi B. et al. Factors predicting biochemical response and survival benefits following radioligand therapy with [177 Lu] Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. Eur J Nucl Med Mol Imaging 2021; 1-14
• 8 Ahmed ME, Lee MS, Mahmoud AM. et al. Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis 2023; 1-5
• 9 Lehner K, Ahmed ME, Bole R. et al. Effect of early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting on cancer-specific survival in metastatic castrate-resistant prostate cancer. American Society of Clinical Oncology 2023;
• 10 Kostos L, Buteau JP, Hofman MS. et al. Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 2023;15. .
• 11 Yordanova A, Linden P, Hauser S. et al. The value of tumor markers in men with metastatic prostate cancer undergoing [177Lu] Lu-PSMA therapy. The Prostate 2020; 80 (01) 17-27
• 12 Poteska R, Rahbar K, Semjonow A. et al. The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide. BMC cancer 2022; 22 (01) 1-11
• 13 Vatsa R, Sood A, Vadi SK. et al. 225Ac-PSMA-617 radioligand posttherapy imaging in metastatic castrate-resistant prostate cancer patient using 3 photopeaks. Clin Nucl Med 2020; 45 (06) 437-438
• 14 Araujo JC, Trudel GC, Saad F. et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol 2013; 14 (13) 1307-1316
• 15 Bryce A, Alumkal J, Armstrong A. et al. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis 2017; 20 (02) 221-227
• 16 Zisser L, Yu J, Oszwald A. et al. Response to [177Lu] Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases. Nucl Med Commun 2022; 43 (11) 1113